Paul Dremsek

Dr. Paul Dremsek

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2021 in Genes
Verified
Journal Article
Open access
PDF file
PDPaul Dremsek
Paul Dremsek
TSThomas Schwarz
Thomas Schwarz
BWBeatrix Weil
Beatrix Weil
AMAlina Malashka
Alina Malashka
FLFranco Laccone
Franco Laccone
JNJuergen Neesen
Juergen Neesen
In recent years, optical genome mapping (OGM) has developed into a highly promising method of detecting large-scale structural variants in human genomes. It is capable of detecting structural variants considered difficult to detect by other current methods. Hence, it promises to be feasible as a first-line diagnostic tool, permitting insight into a new realm of previously unknown variants. However, due to its novelty, little experience with OGM is available to infer best practices for its application or to clarify which features cannot be detected. In this study, we used the Saphyr system (Bionano Genomics, San Diego, CA, USA), to explore its capabilities in human genetic diagnostics. To this end, we tested 14 DNA samples to confirm a total of 14 different structural or numerical chromosomal variants originally detected by other means, namely, deletions, duplications, inversions, trisomies, and a translocation. Overall, 12 variants could be confirmed; one deletion and one inversion could not. The prerequisites for detection of similar variants were explored by reviewing the OGM data of 54 samples analyzed in our laboratory. Limitations, some owing to the novelty of the method and some inherent to it, were described. Finally, we tested the successful application of OGM in routine diagnostics and described some of the challenges that merit consideration when utilizing OGM as a diagnostic tool.

21 November 2021 in Genes
Verified
Journal Article
Open access
PDF file
ASAnna Clara Schnause
Anna Clara Schnause
KKKatalin Komlosi
Katalin Komlosi
BHBarbara Herr
Barbara Herr
JNJuergen Neesen
Juergen Neesen
PDPaul Dremsek
Paul Dremsek
BGBirgitta Glaeser
Birgitta Glaeser
Marfan syndrome (MFS) is a hereditary connective tissue disease caused by heterozygous mutations in the fibrillin-1 gene (FBN1) located on chromosome 15q21.1. A complex chromosomal rearrangement leading to MFS has only been reported in one case so far. We report on a mother and daughter with marfanoid habitus and no pathogenic variant in the FBN1 gene after next generation sequencing (NGS) analysis, both showing a cytogenetically reciprocal balanced translocation between chromosomes 2 and 15. By means of fluorescence in situ hybridization of Bacterial artificial chromosome (BAC) clones from the breakpoint area on chromosome 15 the breakpoint was narrowed down to a region of approximately 110 kb in FBN1. With the help of optical genome mapping (OGM), the translocation breakpoints were further refined on chromosomes 2 and 15. Sequencing of the regions affected by the translocation identified the breakpoint of chromosome 2 as well as the breakpoint of chromosome 15 in the FBN1 gene leading to its disruption. To our knowledge, this is the first report of patients with typical clinical features of MFS showing a cytogenetically reciprocal translocation involving the FBN1 gene. Our case highlights the importance of structural genome variants as an underlying cause of monogenic diseases and the useful clinical application of OGM in the elucidation of structural variants.

9 December 2024 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
PDPaul Dremsek
Paul Dremsek
ASAnna Schachner
Anna Schachner
TRTheresa Reischer
Theresa Reischer
EKElisabeth Krampl-Bettelheim
Elisabeth Krampl-Bettelheim
DBDieter Bettelheim
Dieter Bettelheim
JNJürgen Neesen
Jürgen Neesen
Background Current standard-of-care (SOC) methods for genetic testing are capable of resolving deletions and sequence variants, but they mostly fail to provide information on the breakpoints of duplications and balanced structural variants (SV). However, this information may be necessary for their clinical assessment, especially if the carrier’s phenotype is difficult to assess and/or carrier analysis of relatives is not viable. A promising approach to solving such challenging cases arises with access to optical genome mapping (OGM) but has not been systematically explored as of yet. Methods In this retrospective study, we evaluated diagnostic cases from a 1-year period (2023) in which an SV discovery by SOC methods (microarray, karyotyping and whole-exome sequencing) was followed up by OGM, with the objective to unlock clinically relevant information about the SV. Results Seven cases were shown by SOC methods to bear potential pathogenic SVs and were consequently followed up by OGM. Of these, six were solved by the additional use of OGM alone. One case required sequencing after OGM analysis to further specify the SV’s breakpoints. In all seven cases, OGM was crucial for determining the clinical relevance of the detected SV. Conclusion This study describes the use of OGM as a valuable method for characterising duplications and balanced SVs. Often, this additional information does not add to the quality of a clinical report. However, for a subset of patients, these data are critical, especially in the prenatal setting or when no familial analyses are possible.

18 February 2026 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
CDCeren Damla Durmaz
Ceren Damla Durmaz
NLNaz Güleray Lafcı
Naz Güleray Lafcı
DEDilsu Dicle Erkan
Dilsu Dicle Erkan
ÖAÖmer Çağrı Akçin
Ömer Çağrı Akçin
NBNesibe Bulut
Nesibe Bulut
ÖDÖmer Dizdar
Ömer Dizdar
Hereditary epidermodysplasia verruciformis (EV) represents a paradigmatic inherited cutaneous syndrome linking viral susceptibility, immunity, and oncogenesis. Although biallelic variants in CIB1 , TMC6 , and TMC8 —encoding components of the keratinocyte-intrinsic antiviral complex—underlie most cases, the full mutational spectrum and its oncologic implications remain incompletely defined. We performed integrated genomic, histopathological, and longitudinal clinical analyses in six affected individuals from five unrelated families with confirmed hereditary EV. Comprehensive short-read sequencing, copy-number assessment, and optical genome mapping (OGM) were used to delineate the underlying genetic alterations, followed by long-range PCR and Sanger validation. Pathogenic or likely pathogenic germline variants affecting TMC6 or TMC8 were identified in all probands, providing molecular confirmation of disease. Four variants were novel, including splice-site, frameshift, and in-frame deletions. In one proband, OGM revealed a previously unrecognised complex del–inv–del structural variant spanning both TMC6 and TMC8 —the first reported example in hereditary EV. This rearrangement, confirmed at base-pair resolution, co-segregated with a synonymous TMC8 variant that served as a practical haplotypic marker for carrier testing. Clinically, all patients developed cutaneous squamous cell carcinoma (SCC), and several exhibited multifocal or aggressive disease, underscoring the deterministic malignant potential of hereditary EV. This study broadens the genetic and phenotypic spectrum of TMC6/TMC8 -associated EV, establishes complex structural rearrangement in the molecular etiology, and consolidates hereditary EV as a recessive cancer predisposition syndrome. Integrating high-resolution genome mapping into diagnostic workflows may uncover concealed allelic architecture in unresolved hereditary cancer syndromes.

1 August 2025 in Life
Verified
Journal Article
Open access
PDF file
EKEva Karner
Eva Karner
LKLara Krepler
Lara Krepler
PPPetra Pateisky
Petra Pateisky
GAGrill Agnes
Grill Agnes
PDPaul Dremsek
Paul Dremsek
SSStephanie Springer
Stephanie Springer
Hypoplastic or absent fetal nasal bone (NB) is a significant soft marker in the risk assessment for aneuploidies. This study aimed to evaluate prenatal findings and perinatal outcomes in fetuses with absent or hypoplastic NB managed at our center. This retrospective analysis was conducted at the Department of Obstetrics at the Medical University of Vienna and including all cases with an absent or hypoplastic fetal NB between 2004 and 2022. Clinical data were extracted and analyzed using descriptive statistics. A total of 149 cases were included. Of these, 51% had chromosomal abnormalities, with trisomy 21 present in 30.9%. Malformations were identified in 55% of cases, most commonly congenital heart defects (34.9%) and facial dysmorphism (28.9%). Eighteen fetuses (12.1%) had structural anomalies without genetic disorders. In 32.9% (n = 49), the NB anomaly was isolated. Our findings show that only half of the cases had chromosomal abnormalities, and over half of the pregnancies resulted in live births with generally favorable perinatal outcomes. However, the presence of additional ultrasound abnormalities significantly increased the risk of adverse outcomes. Therefore, detection of a fetal NB anomaly should prompt comprehensive ultrasound evaluation and genetic testing.